Hey Market Enthusiast,

ATNM is already up 17% premarket — and if this keeps rolling, it could be the breakout of the day.

Actinium Pharmaceuticals (NYSE American: ATNM) just delivered a big business update live from Mar-a-Lago — laying out aggressive plans for three blockbuster markets: blood cancers, solid tumors, and cell & gene therapy. (17)

This isn’t hype. It’s cutting-edge radiotherapy backed by real clinical programs, real data coming in 2025, and serious infrastructure moves.

They’re running trials with the National Cancer Institute, targeting leukemia, lung, and head & neck cancer, and even advancing a new approach for sickle cell. 

Plus, they’ve got in-house manufacturing ramping up to meet demand.

💣 The market is waking up. You don’t want to be the one who finds out after the move.

Watch ATNM now! 

(16)

🔹 The Cancer-Fighting Approach That's Turning Heads

Here's the thing about Actinium - they're not following the crowd. 

They've developed something called Antibody Radiation Conjugates (ARCs) that deliver radiation precisely to cancer cells while protecting healthy tissue. 

Their flagship treatment, Iomab-B, accomplished what doctors thought impossible in its Phase 3 SIERRA trial: it helped 22% of elderly patients with relapsed/refractory acute myeloid leukemia achieve complete remission and qualify for potentially life-saving bone marrow transplants. 

The control group? ZERO PERCENT (p<0.0001). (4)

We're talking about real hope for patients who previously had none. 

And it's catching attention in all the right places - these findings were significant enough to be published in the Journal of Clinical Oncology, which is essentially the medical equivalent of getting a Grammy in the oncology world. (5)

🔹 Multiple Paths to Success = Multiple Reasons to Get Excited 🎯

What makes Actinium particularly fascinating is they're not placing all their bets on one treatment. They've built an impressive lineup:

• Iomab-B: Already showing Phase 3 success in AML with special orphan drug status in both US and EU (6)
• Actimab-A: Delivering remarkable 65% response rates when combined with chemotherapy for relapsed AML (7)(8)
• Iomab-ACT: Just received FDA clearance for a trial in sickle cell disease (9)
• Emerging solid tumor programs: Taking their success beyond blood cancers into massive new treatment areas (10)

While others are still at the drawing board, Actinium is already demonstrating success and expanding their horizons. 

They're not just developing treatments - they're potentially redefining what's possible in cancer care.

(16)

🔹 The Human Impact Could Be Enormous 😎

Let's put this in perspective. AML affects about 20,000 new patients every year in the US alone. (11) 

For relapsed patients over 55, bone marrow transplants have traditionally been nearly impossible due to harsh conditioning treatments.

Iomab-B changes everything. Each person who becomes eligible for a transplant gets a second chance at life - something that was previously out of reach. 

When you multiply that across all potential patients, the impact is staggering.

Actinium isn't just improving existing treatments - they're creating possibilities that simply didn't exist before.

🔹 Major Players Are Joining Forces with Actinium 🤝

When big organizations choose to team up with a smaller company, it says something. 

Actinium has secured a partnership with Immedica covering Europe, the Middle East, and North Africa - a significant vote of confidence in their work. (13)

They're also collaborating with world-class institutions like:

• The National Cancer Institute under a special Cooperative Research and Development Agreement (7)
• Memorial Sloan Kettering Cancer Center (14)
• MD Anderson Cancer Center (9)

These partnerships don't just validate what Actinium is doing - they provide additional resources and expertise to move things forward faster without stretching the company thin.

🔹 Financial Foundation That Supports Their Vision 💼

With approximately $83 million in cash as of Q3 2024, Actinium has enough funding through 2025 - sufficient time to reach several key milestones without immediate financial concerns. (12)

Their structure is also favorable, with only about 31 million shares outstanding. (2)

This means when good news hits, there could be significant movement as interest grows.

🔹 The Momentum Is Building - Don't Be Left Wondering "What If?" ⏰

The analysts who track these things remain enthusiastic, with a consensus very strong rating and a median price target of approximately $6 . (15)

Even the most conservative target of around $4 suggests considerable potential from current levels. (15)

ATNM has been establishing stronger foundations since January 2025 - a classic signal that something positive is brewing. Technical indicators are improving, with key metrics turning upward.

🔹 Why This Matters Right Now ⚡

Actinium is approaching several potential game-changing developments: (16)

• Beginning of the new Iomab-B trial
• Possible U.S. partnership announcement
• Additional results from the Actimab-A combinations
• Progress with the Iomab-ACT program

Any one of these events could trigger a significant shift in how people view this pioneering company.

The Bottom Line 📊

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) represents something rare: a group with positive Phase 3 data, multiple approaches to success, strong partnerships, and solid financial footing - yet still flying somewhat under the mainstream radar.

People who recognize potential early are already paying attention. 

With multiple exciting developments on the horizon and growing momentum, this could be your chance to get familiar with Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) before everyone else catches on.

This is one of those stories you'll want to follow closely now!

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/quote/ATNM/

2. https://finance.yahoo.com/quote/ATNM/key-statistics/
3. https://www.actiniumpharma.com/
4. https://bit.ly/41L8AsA
5. https://bit.ly/43pydR5
6. https://bit.ly/4ceg0IA
7. https://bit.ly/3FQwTwA
8. https://bit.ly/3QMf2t2
9. https://bit.ly/42fSCa1
10. https://bit.ly/3E19gAU
11. https://bit.ly/4caU80K
12. https://bit.ly/4c1JQjc
13. https://bit.ly/3DSxflO
14. https://bit.ly/3FCRuVn
15. https://bit.ly/3RisrsX
16. https://bit.ly/4hKfKBW

17. https://bit.ly/3FGD9Hm 

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 03/25/2025 and ending on 03/26/2025 (the “Campaign”) to publicly disseminate information about Actinium Pharmaceuticals, Inc. (ATNM:US). Momentum Media LLC has been compensated $7,500.00 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.